Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder

Impact · against what's priced in

PTGX is transitioning from a high-risk biotech to a high-margin royalty company, bolstered by the FDA approval of MIMRYLO and a $300 million buyback. While these developments are fundamentally strong, the market has already integrated the approval and the associated cash infusions into the current valuation.

PTGX+0.40

No priced-in read yet